The U.S. Food and Drug Administration approved Blueprint Medicines Corp.’s oral therapy to treat a rare form of cancer that affects the stomach and small intestine.

RedHill Biopharma’s combination antibiotic Talicia met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.